文献速递免疫规划卫生政策与健康促进

疫苗真实世界效果与价值评估的考量:成人乙肝疫苗接种案例

Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination.
PubMed 文献 · Vaccine · 2021-08-14

本研究提出结合血清保护率与方案完成率估算有效疫苗保护率(eVPR),并计算每保护患者成本(CPP),用于比较两种成人乙肝疫苗的真实世界效果与成本效益。结果显示,在一般成人及糖尿病患者中,HepB-CpG的eVPR更高且CPP更低,提示其更具价值优势。

要点

  • HepB-CpG在成人中eVPR为68.0%,高于HepB-Alum的41.6%。
  • HepB-CpG的CPP为$331.31,比HepB-Alum低$45.67(95%CI:$36.66,$55.19)。
  • 糖尿病患者中HepB-CpG的CPP比HepB-Alum低$149.60(95%CI:$80.29,$195.63)。

核心结论

  • 使用eVPR和CPP可评估疫苗真实世界效果与价值,HepB-CpG比HepB-Alum更有效且更具价值优势。

研究设计与样本

  • 本研究基于两种乙肝疫苗方案(HepB-CpG两剂与HepB-Alum三剂)的3期头对头临床试验血清保护率数据及真实世界头对头依从性数据,计算一般成人及糖尿病患者的eVPR和CPP。

主要发现

  • 在一般成人中,HepB-CpG的eVPR为68.0%,HepB-Alum为41.6%。
  • HepB-CpG的CPP为$331.31,HepB-Alum为$377.09,HepB-CpG低$45.67(95%CI:$36.66,$55.19)。
  • 在糖尿病患者中,HepB-CpG的CPP为$367.57,HepB-Alum为$517.37,HepB-CpG低$149.60(95%CI:$80.29,$195.63)。

临床怎么用

  • 疫苗选择时可结合eVPR和CPP评估真实世界效果与成本效益,HepB-CpG在成人和糖尿病患者中显示更优价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the absence of field efficacy studies, estimating the real-world effectiveness of vaccines may consider immunogenicity from randomized controlled clinical trials and real-world adherence. Combining seroprotection rates (SPRs) with regimen completion rates gives an estimate of an effective vaccine protection rate (eVPR), which can be leveraged to evaluate real-world cost-effectiveness by linking it with vaccine costs to estimate the cost-per-protected patient (CPP). METHODS: This study evaluated eVPR and CPP as estimates of vaccine clinical- and cost-effectiveness of two-dose (HepB-CpG) and three-dose (HepB-Alum) hepatitis B virus (HBV) vaccines in the general adult population and a subpopulation with diabetes mellitus. eVPR was calculated from head-to-head SPR data from phase 3 clinical trials directly comparing HepB-CpG and HepB-Alum vaccine regimens and real-world head-to-head adherence data. CPP was calculated as the average cost of each regimen divided by eVPR. RESULTS: Higher eVPR in the adult population was achieved with HepB-CpG (68.0%) versus HepB-Alum (41.6%), reflecting the combination of higher SPR and vaccine regimen completion. The CPP for HepB-CpG ($331.31) was $45.67 (95% CI: $36.66, $55.19) less than HepB-Alum ($377.09). Greater savings were observed among persons with diabetes, with CPP $149.60 (95% CI: $80.29, $195.63) lower with HepB-CpG ($367.57) than HepB-Alum ($517.37). CONCLUSIONS: Metrics estimating vaccine real-world effectiveness and value may guide informed decisions in vaccine selection. For example, using eVPR and CPP, HepB-CpG represents a more effective, value-advantaged approach than HepB-Alum toward reducing HBV infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Janssen RS, Bruxvoort K, Jacobsen SJ, et al. Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination. Vaccine. 2021. PMID: 34404556. doi:10.1016/j.vaccine.2021.07.100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。